We found hard evidence corroborating this belief in a study conducted by Afshar-Sterle and coworkers, which showed that the loss of the tumor-suppressor function of the gene BLIMP1 or deregulated expression of the BCL6 oncogene occurs in a large portion of B-cell lymphomas in human patients, however, the deliberate introduction of Blimp1 deficiency or Bcl6 overexpression in the B cells of mice does not precipitate lymphoma unless the T-cell receptor CD28- and Fas-ligand activities are simultaneously impaired in the CD8+ Tc cells [5]. The gene discussed is CD28; the disease is B-cell non-Hodgkin lymphoma.